A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
Conditions: B-cell Non-Hodgkin ' s Lymphoma Interventions: Biological: RJMty19 (CD19-CAR-DNT cells) Sponsors: Guangdong Ruishun Biotech Co., Ltd; Ruijin Hospital; Southern Medical University, China; Beijing GoBroad Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | China Health | Hospitals | Lymphoma | Non-Hodgkin's Lymphoma | Research | Study